Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
2d agoen
From the article
Conditions : Metastatic Myxoid Liposarcoma; Metastatic Synovial Sarcoma; Unresectable Myxoid Liposarcoma; Unresectable Synovial Sarcoma Interventions : Biological: Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C; Procedure: Biopsy Procedure; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging Sponsors : National Cancer Institute (NCI) Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference
Avacta Therapeutics announced platform-validating clinical data for faridoxorubicin (AVA6000), a tumor-activated oncology drug using its pre
avacta.com·13d ago
New cancer drug trial offers hope for patients with rare aggressive tumour
Reading Chronicle·1d ago
FDA-approved drug may finally help immunotherapy defeat rare liver cancer
ScienceDaily·13d ago
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
doi.org·6d ago
New drug for cancer patients with ‘limited’ treatment options enters clinical trial
The Independent·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.